Payment overview · 2025
General Payments
$556.66
33 reported records · 12 companies
Healthcare provider profile · identity verified
Cynthia Mills, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUTCHINSON, KS · NPI 1124099569
Verified facts
What the public records show
CMS Open Payments records show Cynthia Mills, MD received $556.66 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.77 | 37.5% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.35 | 12.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.57 | 11.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.87 | 6.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.66 | 5.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.01 | 5.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.51 | 4.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.86 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.31 | 3.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.36 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.78 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.61 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $556.66 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $149.81 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.64 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.35 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $49.36 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $49.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $9.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 891 | 201 |
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 198 |
| Losartan Potassium | Losartan Potassium | 692 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 146 |
| Potassium Chloride | Potassium Chloride | 484 | 124 |
| Escitalopram Oxalate | Escitalopram Oxalate | 391 | 90 |
| Omeprazole | Omeprazole | 383 | 110 |
| Gabapentin | Gabapentin | 337 | 85 |
| Simvastatin | Simvastatin | 331 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 72 |
| Metformin Hcl | Metformin Hcl | 273 | 69 |
| Sertraline Hcl | Sertraline Hcl | 247 | 68 |
| Metformin Hcl Er | Metformin Hcl | 235 | 63 |
| Lisinopril | Lisinopril | 223 | 56 |
| Ozempic | Semaglutide | 222 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 62 |
| Furosemide | Furosemide | 205 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 190 | 47 |
| Trazodone Hcl | Trazodone Hcl | 174 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 172 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 27 |
| Atenolol | Atenolol | 146 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 33 |
| Donepezil Hcl | Donepezil Hcl | 111 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 28 |
| Eliquis | Apixaban | 105 | 18 |
| Alendronate Sodium | Alendronate Sodium | 103 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 21 |
| Glimepiride | Glimepiride | 97 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 24 |
| Warfarin Sodium | Warfarin Sodium | 95 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 30 |
| Meloxicam | Meloxicam | 91 | 27 |
| Prednisone | Prednisone | 89 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 21 |
| Allopurinol | Allopurinol | 78 | 18 |
| Montelukast Sodium | Montelukast Sodium | 78 | 14 |
| Tramadol Hcl | Tramadol Hcl | 78 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 67 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 14 |
| Lorazepam | Lorazepam | 65 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 11 |
| Fenofibrate | Fenofibrate | 60 | 15 |
| Novolog Flexpen | Insulin Aspart | 59 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 49 |
| Clonazepam | Clonazepam | 54 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Estradiol | Estradiol | 52 | 22 |
| Synthroid | Levothyroxine Sodium | 52 | 14 |
| Alprazolam | Alprazolam | 50 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 21 |
| Famotidine | Famotidine | 49 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 26 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Lovastatin | Lovastatin | 42 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 24 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Levetiracetam Er | Levetiracetam | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Naproxen | Naproxen | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $556.66 · 33 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, GEMTESA, Kerendia, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SHINGRIX, Tymlos, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error